Skip to content
Peptigraph home

Mazdutide Phase 3 trial (NCT05628311)

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study (DREAMS-1) to Evaluate the Efficacy and Safety of IBI362 in Chinese Type 2 Diabetes Patients With Poor Glycemia Control Only Through Diet and Exercise

Registry record checked

At a glance

Phase
Phase 3
Status
Completed
Enrolment
319
actual
Start
6 Jan 2023 (actual)
Primary completion
25 Oct 2023 (actual)
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Design

Arms and doses

NCT05628311 study arms
ArmTypeInterventionsDescription
IBI362 4.0 mgExperimentalDrug: IBI362①2mg, subcutaneously (SC), once a week\* 4weeks; ②4mg, SC, once a week\* 44weeks.
IBI362 6.0 mgExperimentalDrug: IBI362①2mg, SC, once a week\* 4weeks; ②4mg, SC, once a week\* 4weeks; ③6mg, SC, once a week\* 40weeks.
placeboPlacebo comparatorOther: placebo* placebo, SC, once a week\* 24weeks; * 2mg, SC, once a week\* 4weeks; * 4mg, SC, once a week\* 4weeks; * 6mg, SC, once a week\* 16weeks.
Endpoints

Primary endpoint

NCT05628311 primary outcomes
MeasureTime frame
HbA1c change from baseline at week 24Baseline, 24 weeks
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05628311 secondary outcomes
MeasureTime frame
Proportion of subjects with HbA1c<7.0% at week 24Baseline, 24 weeks
Safety, Incidence and severity of adverse events and correlation with study drug;Baseline to 52 weeks
Time to peak plasma concentration (Tmax)Baseline to 52 weeks
Time to peak plasma concentration (Cmax)Baseline to 52 weeks
area under curve (AUC)Baseline to 52 weeks
volume distribution (V)Baseline to 52 weeks
half-life (half-life, T1/2)Baseline to 52 weeks
clearance rate (clearance, CL)Baseline to 52 weeks
To assess changes in PD parameters fasting insulin at different time points before and after administration.Baseline to 52 weeks
To assess changes in PD parameters fasting C-peptide at different time points before and after administration.Baseline to 52 weeks
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study (DREAMS-1) to Evaluate the Efficacy and Safety of IBI362 in Chinese Type 2 Diabetes Patients With Poor Glycemia Control Only Through Diet and ExerciseClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.